Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

2023658 citationsJournal Articlegreen Open Access

Authors

Ingo K. Mellinghoff · Memorial Sloan Kettering Cancer Center

Martin J. van den Bent · Rabin Medical Center

Deborah T. Blumenthal · Sorbonne Université

Mehdi Touat · Institut du Cerveau

Katherine B. Peters · Rabin Medical Center

Jennifer Clarke · University of California, San Francisco

Joe Mendez

Abstract

In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. (Funded by Servier; INDIGO ClinicalTrials.gov number, NCT04164901.).

Topics & Keywords

Glioma Diagnosis and Treatment Sarcoma Diagnosis and Treatment Chromatin Remodeling and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 7, pp. 589-601

DOI: 10.1056/nejmoa2304194

Field-Weighted Citation Impact: 187.24